Loading company…
France-based nanomedicine company developing AGuIX nanoparticles to improve precision radiotherapy for cancer.
Founded in 2015 in France, NH TherAguix SAS develops its AGuIX nanoparticle to enhance radiotherapy by targeting tumors directly, with potential use across cancers. CEO Vincent Carrère led the company's Series A round of EUR 4.06 million on June 3, 2021, at a current valuation of EUR 33.023 million. In 2022 the company recorded zero revenue and an EBITDA of EUR -6,219,521.1.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in